Bitcoin groundbreakers share personal stories of how Bitcoin is changing lives for the better. Host Mauricio Di Bartolomeo, co-founder and CSO of Ledn, speaks with leading Bitcoin voices, entrepreneurs, and human rights advocates to hear their unique journey and practical real-world examples of how Bitcoin has made a positive impact in their lives. Brought to you by Ledn, a leading financial services company built for Bitcoin & digital assets. Ledn offers a suite of lending, saving and tradi ...
…
continue reading
A tartalmat a Proactive Investors biztosítja. Az összes podcast-tartalmat, beleértve az epizódokat, grafikákat és podcast-leírásokat, közvetlenül a Proactive Investors vagy a podcast platform partnere tölti fel és biztosítja. Ha úgy gondolja, hogy valaki az Ön engedélye nélkül használja fel a szerzői joggal védett művét, kövesse az itt leírt folyamatot https://hu.player.fm/legal.
Player FM - Podcast alkalmazás
Lépjen offline állapotba az Player FM alkalmazással!
Lépjen offline állapotba az Player FM alkalmazással!
Amplia Therapeutics: Advancing Pancreatic Cancer Treatment
MP3•Epizód kép
Manage episode 435437094 series 2891889
A tartalmat a Proactive Investors biztosítja. Az összes podcast-tartalmat, beleértve az epizódokat, grafikákat és podcast-leírásokat, közvetlenül a Proactive Investors vagy a podcast platform partnere tölti fel és biztosítja. Ha úgy gondolja, hogy valaki az Ön engedélye nélkül használja fel a szerzői joggal védett művét, kövesse az itt leírt folyamatot https://hu.player.fm/legal.
Chris Burns, CEO of Amplia Therapeutics, shared promising updates with Steve Darling from Proactive regarding the company’s ongoing Phase 2a clinical trial focused on treating advanced pancreatic cancer. Burns announced that a fifth patient enrolled in the trial has achieved a confirmed partial response, indicating a 30% or greater reduction in the overall size of tumor lesions, which has been maintained over a two-month period with no new tumor lesions appearing. Additionally, Burns reported that six other patients in the trial have shown stable disease at both their two-month and four-month assessment time points. According to RECIST 1.1 criteria, stable disease (SD) is noted when tumor lesions have either reduced in size by less than 30% or have shown minimal to no growth. The Phase 2a ACCENT trial is exploring the efficacy of Amplia Therapeutics’ lead asset, narmafotinib, in treating advanced pancreatic cancer. The trial plans to enroll a total of 50 patients, with the first cohort consisting of 26 patients. Responses to the therapy are monitored every two months, and the recruitment of the second cohort of 24 patients will commence once a minimum of six patients have recorded a confirmed partial or complete response. #proactiveinvestors #ampliatherapeuticslimited #asx #atx #PancreaticCancer #CancerTreatment #ClinicalTrial #Biotech #HealthcareInnovation #Pharmaceuticals #Oncology #CancerResearch #MedicalBreakthrough#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
609 epizódok
MP3•Epizód kép
Manage episode 435437094 series 2891889
A tartalmat a Proactive Investors biztosítja. Az összes podcast-tartalmat, beleértve az epizódokat, grafikákat és podcast-leírásokat, közvetlenül a Proactive Investors vagy a podcast platform partnere tölti fel és biztosítja. Ha úgy gondolja, hogy valaki az Ön engedélye nélkül használja fel a szerzői joggal védett művét, kövesse az itt leírt folyamatot https://hu.player.fm/legal.
Chris Burns, CEO of Amplia Therapeutics, shared promising updates with Steve Darling from Proactive regarding the company’s ongoing Phase 2a clinical trial focused on treating advanced pancreatic cancer. Burns announced that a fifth patient enrolled in the trial has achieved a confirmed partial response, indicating a 30% or greater reduction in the overall size of tumor lesions, which has been maintained over a two-month period with no new tumor lesions appearing. Additionally, Burns reported that six other patients in the trial have shown stable disease at both their two-month and four-month assessment time points. According to RECIST 1.1 criteria, stable disease (SD) is noted when tumor lesions have either reduced in size by less than 30% or have shown minimal to no growth. The Phase 2a ACCENT trial is exploring the efficacy of Amplia Therapeutics’ lead asset, narmafotinib, in treating advanced pancreatic cancer. The trial plans to enroll a total of 50 patients, with the first cohort consisting of 26 patients. Responses to the therapy are monitored every two months, and the recruitment of the second cohort of 24 patients will commence once a minimum of six patients have recorded a confirmed partial or complete response. #proactiveinvestors #ampliatherapeuticslimited #asx #atx #PancreaticCancer #CancerTreatment #ClinicalTrial #Biotech #HealthcareInnovation #Pharmaceuticals #Oncology #CancerResearch #MedicalBreakthrough#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
609 epizódok
Tüm bölümler
×Üdvözlünk a Player FM-nél!
A Player FM lejátszó az internetet böngészi a kiváló minőségű podcastok után, hogy ön élvezhesse azokat. Ez a legjobb podcast-alkalmazás, Androidon, iPhone-on és a weben is működik. Jelentkezzen be az feliratkozások szinkronizálásához az eszközök között.